CERS – Cerus Corporation
CERS — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
5.74
Margin Of Safety %
-18
Put/Call OI Ratio
0.32
EPS Next Q Diff
-0.02
EPS Last/This Y
0.02
EPS This/Next Y
0.05
Price
1.84
Target Price
5
Analyst Recom
1.67
Performance Q
-10.24
Upside
-252.2%
Beta
1.65
Ticker: CERS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | CERS | 1.935 | 0.10 | 0.00 | 4409 |
| 2026-03-10 | CERS | 1.77 | 0.10 | 7.33 | 4412 |
| 2026-03-11 | CERS | 1.795 | 0.11 | 95.66 | 4451 |
| 2026-03-12 | CERS | 1.7 | 0.42 | 4.16 | 5704 |
| 2026-03-13 | CERS | 1.7 | 0.42 | 4.16 | 5704 |
| 2026-03-17 | CERS | 1.8 | 0.41 | 0.09 | 6939 |
| 2026-03-18 | CERS | 1.805 | 0.41 | 0.26 | 6939 |
| 2026-03-19 | CERS | 1.765 | 0.41 | 0.00 | 6947 |
| 2026-03-20 | CERS | 1.715 | 0.41 | 27.33 | 6947 |
| 2026-03-23 | CERS | 1.82 | 0.09 | 2.30 | 5142 |
| 2026-03-24 | CERS | 1.775 | 0.09 | 0.00 | 5138 |
| 2026-03-25 | CERS | 1.84 | 0.09 | 45.66 | 5141 |
| 2026-03-26 | CERS | 1.835 | 0.17 | 999.99 | 5505 |
| 2026-03-27 | CERS | 1.785 | 0.37 | 2.30 | 6495 |
| 2026-03-30 | CERS | 1.745 | 0.36 | 999.99 | 6388 |
| 2026-03-31 | CERS | 1.83 | 0.36 | 999.99 | 6388 |
| 2026-04-01 | CERS | 1.88 | 0.32 | 0.00 | 6207 |
| 2026-04-02 | CERS | 1.86 | 0.32 | 0.00 | 6207 |
| 2026-04-06 | CERS | 1.855 | 0.32 | 10.00 | 6207 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | CERS | 1.93 | 0.0 | - | -0.07 |
| 2026-03-10 | CERS | 1.77 | 0.0 | - | -0.07 |
| 2026-03-11 | CERS | 1.79 | 0.0 | - | -0.07 |
| 2026-03-12 | CERS | 1.70 | 0.0 | - | -0.07 |
| 2026-03-13 | CERS | 1.70 | 0.0 | - | -0.07 |
| 2026-03-17 | CERS | 1.80 | 12.5 | - | -0.06 |
| 2026-03-18 | CERS | 1.80 | 12.5 | - | -0.06 |
| 2026-03-19 | CERS | 1.76 | 12.5 | - | -0.06 |
| 2026-03-20 | CERS | 1.72 | 12.5 | - | -0.06 |
| 2026-03-23 | CERS | 1.82 | 12.5 | - | -0.06 |
| 2026-03-24 | CERS | 1.78 | 12.5 | - | -0.06 |
| 2026-03-25 | CERS | 1.85 | 12.5 | - | -0.06 |
| 2026-03-26 | CERS | 1.84 | 12.5 | - | -0.06 |
| 2026-03-27 | CERS | 1.78 | 12.5 | - | -0.06 |
| 2026-03-30 | CERS | 1.75 | 12.5 | - | -0.06 |
| 2026-03-31 | CERS | 1.82 | 12.5 | - | -0.06 |
| 2026-04-01 | CERS | 1.87 | 12.5 | - | -0.06 |
| 2026-04-02 | CERS | 1.87 | 12.5 | - | -0.06 |
| 2026-04-06 | CERS | 1.85 | 12.5 | - | -0.06 |
| 2026-04-07 | CERS | 1.84 | 12.5 | - | -0.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | CERS | -0.60 | 3.69 | 4.27 |
| 2026-03-10 | CERS | -4.28 | 3.69 | 4.27 |
| 2026-03-11 | CERS | -4.28 | 3.69 | 4.25 |
| 2026-03-12 | CERS | -4.28 | 3.69 | 4.25 |
| 2026-03-13 | CERS | -4.28 | 3.69 | 4.25 |
| 2026-03-17 | CERS | -13.01 | 3.97 | 4.25 |
| 2026-03-18 | CERS | -13.01 | 3.97 | 4.25 |
| 2026-03-19 | CERS | -13.01 | 3.97 | 4.25 |
| 2026-03-20 | CERS | -13.01 | 3.97 | 4.25 |
| 2026-03-23 | CERS | -13.01 | 3.89 | 4.25 |
| 2026-03-24 | CERS | -13.01 | 3.89 | 4.25 |
| 2026-03-25 | CERS | -13.01 | 3.89 | 5.74 |
| 2026-03-26 | CERS | -13.01 | 3.89 | 5.74 |
| 2026-03-27 | CERS | -13.01 | 3.89 | 5.74 |
| 2026-03-30 | CERS | -13.01 | 3.88 | 5.74 |
| 2026-03-31 | CERS | -13.01 | 3.88 | 5.74 |
| 2026-04-01 | CERS | -13.01 | 3.88 | 5.74 |
| 2026-04-02 | CERS | -13.01 | 3.88 | 5.74 |
| 2026-04-06 | CERS | -13.01 | 1.56 | 5.74 |
| 2026-04-07 | CERS | -13.01 | 1.56 | 5.74 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.01
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.03
Insider Transactions
-13.01
Institutional Transactions
1.56
Beta
1.65
Average Sales Estimate Current Quarter
51
Average Sales Estimate Next Quarter
58
Fair Value
1.51
Quality Score
45
Growth Score
50
Sentiment Score
51
Actual DrawDown %
77.2
Max Drawdown 5-Year %
-85.4
Target Price
5
P/E
Forward P/E
PEG
P/S
1.72
P/B
5.5
P/Free Cash Flow
318.56
EPS
-0.08
Average EPS Est. Cur. Y
-0.06
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7.58
Relative Volume
0.55
Return on Equity vs Sector %
-51.8
Return on Equity vs Industry %
-36.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
◆
CERS
Healthcare
$1.84
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
45
Range 1M
61.8%
Sup Dist
0.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
8.3%
EPS NY
54.6%
52W%
37.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+57.9% upside
Upside
+57.9%
Quality
45
MoS
-18%
Cerus CorporationSector: Healthcare
Industry: Medical Devices
Employees: 261
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS
Latest News
—
Caricamento notizie per CERS…
stock quote shares CERS – Cerus Corporation Stock Price stock today
news today CERS – Cerus Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch CERS – Cerus Corporation yahoo finance google finance
stock history CERS – Cerus Corporation invest stock market
stock prices CERS premarket after hours
ticker CERS fair value insiders trading